Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
114
resultados
Última actualización
14/09/2026 [07:23:00]
Resumen de: US20260263370A1
The described technology pertains to biotechnology, specifically engineered bacterial systems designed for extracellular delivery of therapeutic proteins in cancer treatment. The disclosed bacteria, such as Salmonella typhimurium, are genetically modified to include plasmid coding for a therapeutic protein, a salicylic acid-inducible promoter operably linked to a lysis protein, and a plasmid retention mechanism. These bacteria are modified to remain extracellular by incorporating knockouts such as flhD, which prevent intracellular invasion of cancer cells. Upon induction with salicylic acid, the bacteria lyse and release therapeutic proteins, such as IFNγ, into the tumor microenvironment, converting the environment from immunosuppressive to immunostimulatory and reducing tumor growth. The system is designed to provide safe and tumor-specific delivery, minimizing systemic toxicity. Applications include treating solid tumors, such as pancreatic and breast cancer.
Resumen de: WO2026184777A1
A Lactobacillus plantarum strain having an antibacterial effect, and the use thereof, wherein the Lactobacillus plantarum has a deposit number of CGMCC No. 33151. The strain exhibits strong tolerance to bile salts and resists gastric acid, and has good acid producing and H2O2-producing capabilities, has a relatively strong antibacterial effect against common pathogenic bacteria such as Staphylococcus aureus, Candida albicans, Escherichia coli, Salmonella and Helicobacter pylori, and is capable of inhibiting urease activity, interfering with Helicobacter pylori colonization, etc. to inhibit Helicobacter pylori infection or alleviate the symptoms of Helicobacter pylori infection, and reduce the disease severity of colitis in mice. The strain can be used in the preparation of a microbial preparation, and has the potential for use in the preparation of a drug for preventing and/or treating diseases caused by Helicobacter pylori infection.
Resumen de: WO2026185254A1
The present invention relates to an attenuated Salmonella strain, particularly a Salmonella typhi Ty21a strain comprising a recombinant DNA molecule comprising at least one eukaryotic expression cassette encoding a fusion protein comprising a targeting unit, a multimerization unit, and an antigenic unit and to a pharmaceutical composition comprising said attenuated Salmonella strain, wherein the composition is for oral administration. Said attenuated Salmonella strain or pharmaceutical composition is further provided for use in preventing and/or treating a disorder or disease selected from the group consisting of cancer, an infectious disease a chronic infectious disease or an autoimmune disease.
Resumen de: WO2026185450A1
Novel antibody for antimicrobial resistance detection Antibodies or fragments thereof are provided that specifically bind to bacterial ribosomal subunit S16 and are useful for capturing RNA of a wide-spectrum of bacteria, thereby improving accuracy and speed of antibiotic resistance diagnostics. The antibody or the fragment thereof comprises a heavy-chain variable region CDR1 comprising the amino acid sequence AMS, a heavy-chain variable region CDR2 comprising SEQ ID NO: 16, a heavy-chain variable region CDR3 comprising SEQ ID NO: 18, a light-chain variable region CDR1 comprising SEQ ID NO: 36, a light-chain variable region CDR2 comprising SEQ ID NO: 38 and a light-chain variable region CDR3 comprising SEQ ID NO: 40.
Resumen de: US20260265313A1
The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.
Resumen de: WO2026187809A2
Provided herein are compounds that target Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Salmonella typhimurium, and are selective over Gram-negative and Gram-positive commensal bacteria, as well as their methods of use.
Resumen de: US20260263534A1
The present disclosure provides a method of treating a solid tumor cancer. The method includes administering a combination to a subject in need thereof. The combination includes at least two chemotherapy agents and a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The present disclosure also provides an anti-tumor agent for use in a method of treating cancer. In such instances, the anti-tumor agent may include the combination.
Resumen de: US20260262663A1
Systems and methods of decontaminating food substances by using cold plasma to enhance the performance of ionized hydrogen peroxide to decontaminate food, and methods of use thereof. Cold plasma activation significantly enhanced the efficacy of hydrogen peroxide mist against bacteria on fresh produce, and the technology may be used to enhance microbial safety. Cold plasma activated ionized hydrogen peroxide (iHP) can be applied on various fresh produce items. In particular, cold plasma enhanced the efficacy of hydrogen peroxide (H2O2) mist against Salmonella.
Resumen de: CN122705692A
本发明提供了一种能响应温度变化从而诱导下游基因表达的重组盐单胞菌及其构建方法和应用。所述重组盐单胞菌利用突变筛选得到的Toll/白介素‑1受体类似蛋白A(TIR‑like protein A,TlpA)构建的37°C及42°C诱导型启动子，并且对该37°C及42°C诱导型启动子进行了全面表征。所述重组盐单胞菌可以实现在30°C升温至37°C及37°C升温至42°C时启动目的基因表达的目的，且采用这种方法实现基因的诱导表达，具有操作简单、成本低的特点。
Resumen de: US20260256858A1
0000 Disclosed herein are processes for extracting muscimol from Amanita mushrooms, and more particularly, from Amanita muscaria, including processes that increase muscimol content and decrease ibotenic acid content, and further including improved processes that produce extract at scale, such as at kilogram scale. In some aspects are methods for selecting Amanita mushroom biomass suitable for the disclosed extraction methods, so as to produce extracts and products that are safe and beneficial for human use. Also disclosed are numerous compositions and formulations made with disclosed extracts, including beverage formulations, having a variety of improvements and advantages over previously known products made from Amanita muscaria.
Resumen de: WO2026180700A1
The present invention provides a modified quorum sensing circuit, wherein the modified quorum sensing circuit comprises a quorum sensing synthase and a quorum sensing receptor, wherein the quorum sensing synthase and the quorum sensing receptor are transcriptionally separated.
Resumen de: US20260248139A1
A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.
Resumen de: US20260248866A1
0000 An object of the present disclosure is to provide (i) a novel bacteriophage having lytic activity against a Salmonella species such as S. enteritidis or a lytic agent including the same, (ii) a bacteriophage having a broad host range against Salmonella species or a lytic agent including the same, (iii) a host-specific bacteriophage or an effective lytic agent for a Salmonella species including the same, or (iv) a bacteriophage or a lytic agent including the same, capable of effectively controlling S. typhimurium, particularly S. typhimurium having multidrug resistance. The present disclosure provides bacteriophages having specific genomic DNA sequences, lytic agents for Salmonella species including the same, and compositions including the same.
Resumen de: US20260248865A1
0000 A bacteriophage having a wide host range for bacteria of the genus Salmonella is provided. The bacteriophage has bacteriolytic activity against bacteria of the genus Salmonella. The bacteriophage has a genomic DNA sequence comprising a gene encoding a tail tip protein consisting of a specific amino acid sequence. Methods of using the bacteriophage are also provided.
Resumen de: CN122609470A
本发明属于生物医药领域，具体涉及一种胸苷依赖型的鼠伤寒沙门氏菌工程菌及其组合物与应用。所述工程菌以鼠伤寒沙门氏菌VNP20009为出发菌株，经敲除胸苷酸合成酶基因thyA和插入腺苷脱氨酶编码基因，获得生长依赖外源嘧啶核苷酸、胞内表达或外膜表达腺苷脱氨酶的工程菌；胞内表达腺苷脱氨酶的工程菌为鼠伤寒沙门氏菌VNP20009‑cADD，保藏号为CGMCC No.37959；外膜表达腺苷脱氨酶的工程菌为鼠伤寒沙门氏菌VNP20009‑wADD，保藏号为CGMCC No.37956。该工程菌可肿瘤靶向定植、安全性更高，能在肿瘤局部降解腺苷、解除免疫抑制，联合放疗或免疫检查点抑制剂时可显著抑制实体瘤生长。
Resumen de: US20260242806A1
0000 The invention relates to re-engineering of a natural microbial syringe for loading of effector proteins that are not naturally found as cargo of the specific syringe. The cargo, that is one or more effector protein and proteins required for packing, can be up to 300 kDa and can be proteins such as toxins, therapeutic proteins, and gene modification tools. The re-engineering of the natural syringe result in a contractile injection system that allows packing of large cargo and cargo combinations, such as toxin-chimeras. The system comprises a Conserved Virulence Cassette encoding the syringe structure and is co-expressed with a sequence encoding cargo and a signal peptide. The signal peptide comprises a packing motif that enables packing of cargo into the syringe. The contractile injection system can be used for agricultural purposes as well as for medicinal purposes.
Resumen de: US20260240985A1
0000 The present invention relates to a non-viable bacterium cell wherein an immunogenic polypeptide fused to an auto-transporter comprising transmembrane linker and a trans-porter domain is displayed on the surface of the cell, and to a preparation comprising such non-viable cells. The preparation is useful as an oral vaccine.
Resumen de: US20260243764A1
Described herein is a biosensor for detecting the presence of a target molecule in a sample. The biosensor comprises: a polymeric hydrogel; a colorimetric indicator entrapped in the polymeric hydrogel; and an oligonucleotide that crosslinks the polymeric hydrogel, wherein the oligonucleotide is separated in the presence of the target molecule, thereby releasing the colorimetric indicator from the hydrogel.
Resumen de: US20260242416A1
Antimicrobial peptides (AMPs) exhibiting broad spectrum antimicrobial activity are described. Such peptides are useful in treating or preventing infections and other conditions, and are of special interest for treating antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach leading to identification of numerous antimicrobial peptides from known genomic sequences is described.
Resumen de: AU2026208127A1
Compositions, methods, kits, and uses are provided for detecting the presence of Salmonella, Shigella, Campylobacter, and Shigatoxigenic Escherichia coli (STEC) in samples. In some embodiments, the compositions, methods, kits, and uses comprise one or more oligonucleotides or the use of one or more oligonucleotides. ul u l
Resumen de: WO2022032100A2
The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Cell Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.
Resumen de: WO2025080776A2
Aspects of the invention described herein relate to a vaccine composition comprising at an antigenic polysaccharide and an immunomodulatory amount of a sialic acid binding moiety, wherein the sialic acid binding moiety comprises sialic acid binding domain (SBD) which is not fused to an antigenic polypeptide.
Resumen de: KR20260124251A
본 발명은 TolC 유전자가 결손된 신규 살모넬라 엔테리카 타이피뮤리움(Salmonella enterica Typhimurium) CK139 균주 및 상기 균주가 분비하는 단백질에 관한 것으로, 살모넬라 엔테리카 타이피뮤리움(Salmonella enterica Typhimurium) 균주에서 외막 단백질인 TolC에 대한 유전자가 결손된 돌연변이 균주인 살모넬라 엔테리카 타이피뮤리움(Salmonella enterica Typhimurium) CK139 균주가 철 이온의 농도에 따라 분비 단백질의 패턴이 유의적으로 변화되는 것을 확인하고, 낮은 철 이온 농도에서 에코틴(ecotin) 단백질의 분비가 유의적으로 증가되는 것을 확인하였으며, 상기 CK139 균주 또는 에코틴(ecotin) 단백질을 마우스에 주사한 결과 염증성 장질환이 악화됨을 확인함에 따라 상기 CK139 균주 또는 에코틴(ecotin) 단백질을 염증성 장질환의 악화 인자를 확인하고, 이를 이용하여 염증성 장질환 동물 모델의 제조 방법을 제공한다.
Resumen de: CN122582271A
本发明公开一种基于细菌的肿瘤原位疫苗，包括灭活细菌和腺苷脱氨酶，所述灭活细菌为大肠杆菌(Escherichia coli) Nissle 1917或减毒鼠伤寒沙门氏菌(VNP 20009)中的任意一种或两种。本发明的肿瘤原位疫苗对宿主脏器无明显毒副作用，具有良好的安全性，生产制备工艺简单、成本低；可通过瘤内注射方式刺激机体先天性和适应性免疫系统，增强抗肿瘤免疫，抑制肿瘤细胞生长，有效预防肿瘤的发生发展和复发转移。
Nº publicación: JP2026131609A 14/08/2026
Solicitante:
エンエーセーオンコイミュニティアクスイェセルスカプ
Resumen de: CN115715198A
The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain, the Salmonella typhi Ty21a strain comprising a DNA molecule, the DNA molecule comprising an eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the invention relates to the application of the DNA vaccine to prevention and/or treatment of the coronavirus disease COVID-19 or SARS-CoV-2 infection.
BOPI
Sede Electrónica
